Researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD) have reported encouraging results from an early-stage clinical trial, finding that an experimental intranasal vaccine generated a broad immune response against multiple strains of H5N1 “bird flu.”
Early-stage clinical trial demonstrates promise of intranasal influenza vaccine in generating broad immunity

